Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Serotonin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 7/20 | 0.76 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.76 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.76 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.76 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.76 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.76 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.71 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.71 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.63 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.58 |
| ▸ | MTOR known ✓ | P42345 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 5/20 | 0.76 |
| ▸ | HTR1B | P28222 | 4/20 | 0.76 |
| ▸ | TSHR | P16473 | 4/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | HTR5A | P47898 | 3/20 | 0.76 |
| ▸ | HTR6 | P50406 | 3/20 | 0.76 |
| ▸ | HTR1D | P28221 | 3/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serotonin SCHEMBL29042320 | 1.00 | HTR2C (0.76) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL7091769 | 0.99 | HTR2C (0.78) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL7091772 | 0.99 | HTR2C (0.78) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL31141325 | 0.99 | HTR2C (0.78) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL9504033 | 0.90 | HTR2C (0.64) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL5833418 | 0.89 | HTR2C (0.85) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL28307138 | 0.89 | HTR2C (0.85) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL396997 | 0.89 | HTR2C (0.97) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL28466208 | 0.88 | HTR2C (0.83) | HTR2CHTR1AHTR7HTR1BHTR2A | |
| Serotonin SCHEMBL1495 | 0.87 | HTR2C (1.00) | HTR2CHTR1AHTR7HTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033029-A1 | Treating Digestive Tract Conditions | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-02-07 | — | — | US | claimed |
| WO-2005107473-A2 | TREATING DIGESTIVE TRACT CONDITIONS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| US-9938525-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to cell types | NLIFE THERAPEUTICS, S.L. (ES) | 2018-04-10 | — | — | US | disclosed |
| US-20170073679-A1 | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types | NLIFE THERAPEUTICS, S.L. (ES) | 2017-03-16 | — | — | US | disclosed |
| US-20150315575-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | PALOMO LIMITED (CY) | 2015-11-05 | — | — | US | disclosed |
| US-20140315795-A1 | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types | NLIFE THERAPEUTICS, S.L. (ES) | 2014-10-23 | — | — | US | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20080033029-A1 | Treating Digestive Tract Conditions | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-02-07 | — | — | US | disclosed |
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005107473-A2 | TREATING DIGESTIVE TRACT CONDITIONS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315575-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | MSR1, HAVCR2, SNRPE | HTR2C 3987/4885HTR1A 4213/4885HTR2A 3317/4885 |
| US-20140315795-A1 | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types | MSR1, HAVCR2, SNRPE | HTR2C 4003/4885HTR1A 4237/4885HTR2A 3387/4885 |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | HTR2C 8/4885HTR1A 4/4885HTR2A 3/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | HTR2C 10/4885HTR1A 6/4885HTR2A 3/4885 |
| US-20170073679-A1 | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types | MSR1, HAVCR2, SNRPE | HTR2C 4003/4885HTR1A 4237/4885HTR2A 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.